We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Collaboration to Develop Diagnostic Test for Purpura

By Labmedica staff writers
Posted on 07 Dec 2006
Ciphergen (Fremont, California, USA) and Ohio State University Research Foundation (OSURF, Columbus, OH, USA) have announced a collaborative agreement to develop and clinically validate a diagnostic test to detect thrombotic thrombocytopenic purpura (TTP), a hematologic disease. More...


Under the terms of the agreement, OSURF and Ciphergen will optimize the assay to measure enzyme and antibody inhibition activity, and will jointly conduct multi-center studies to validate the test. Financial terms of the agreement were not disclosed.

TTP is a blood disorder characterized by low platelets, low red blood cell count (caused by premature breakdown of the cells), neurologic abnormalities, and sometimes abnormalities in kidney function. In most cases, this disease is caused by a deficiency in auto-antibodies to an enzyme called a disintegrin and metalloproteinase with a thrombospondin type 1 motif 13 (ADAMTS-13). Loss of this enzyme causes platelet clumping and red blood cell destruction.

"A clinical diagnostic test that can rapidly detect deficiencies in the enzyme activity associated with TTP will help physicians more effectively manage this devastating disease,” said Haifeng M. Wu, M.D., assistant professor of pathology and medicine and director of the clinical coagulation laboratory at Ohio State University Medical Center. "This test will help physicians determine when to initiate plasma exchange and monitor response to this therapy.” Working with Dr. Wu, Ciphergen intends to optimize a surface-enhanced laser desorption/ionization (SELDI)-based test, which will be reproducible and will accurately measure the product of the enzymatic reaction that underlies this disease.

Annual testing opportunities are needed to diagnose patients with TTP, evaluate patient responses to therapy, and monitor patients during clinical remission to prevent recurrences of the disease.

Ciphergen Biosystems is dedicated to the discovery, development, and commercialization of novel high-value diagnostic tests that help physicians diagnose, treat, and improve outcomes for patients. The company has ongoing diagnostic programs in oncology/hematology, cardiology, and women's health with a focus on ovarian cancer.



Related Links:
Ciphergen
Ohio State University Research Foundation

New
Gold Member
Aspiration System
VACUSAFE
POC Helicobacter Pylori Test Kit
Hepy Urease Test
New
HPV Molecular Test
BD Onclarity HPV Assay
New
Total Laboratory Automation Solution
SATLARS Mini T8
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: Accurate immunotherapy selection for esophageal and GEJ carcinomas depends on consistent PD-L1 assessment (credit: Adobe Stock)

FDA Approval Expands Use of PD-L1 Companion Diagnostic in Esophageal and GEJ Carcinomas

Esophageal and gastroesophageal junction carcinomas (GEJ) have a poor prognosis, with approximately 16,250 deaths in the United States in 2025 and a five-year relative survival of 21.9%.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.